Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.

PloS one - 1 Jan 2014

Wada Makoto, Horinaka Mano, Yamazaki Toshikazu, Katoh Norito, Sakai Toshiyuki

Abstract excerpt

Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates. Despite these advances, a treatment strategy targeting NRAS-mutated melanoma has not yet been elucidated. We discovered CH5126766/RO5126766 as a potent and selective dual RAF/MEK inhibitor currently under early clinical trials. We examined the activity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to BRAF gene
Share to KRAS gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, ras

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25422890
DOI: 10.1371/journal.pone.0113217
PMCID: PMC4244135

Genes

BRAF
NRAS
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PMID 25422890Read ↗

Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

The role of MEK inhibitors in the treatment of metastatic melanoma.Semantic proximity Read ↗

MEK and RAF inhibitors for BRAF-mutated cancersSemantic proximity Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.Semantic proximity Read ↗

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity Read ↗

Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.Semantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.Semantic proximity Read ↗

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.